LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Modjtahedi, H.; Khelwatty, S.A.; Kirk, R.S.; Seddon, A.M.; Essapen, S.; Del Vecchio, C.A.; Wong, A.J.; Eccles, S. (2012)
Publisher: Nature Publishing Group
Journal: British Journal of Cancer
Languages: English
Types: Article
Subjects: Molecular Diagnostics, ICR10, EGFR, EGFRvIII, biological, immunohistochemistry, EGFR PharmDx
Background:The human epidermal growth factor receptor (EGFR) is an important therapeutic target in oncology, and three different types of EGFR inhibitors have been approved for the treatment of cancer patients. However, there has been no clear association between the expression levels of EGFR protein in the tumours determined by the FDA-approved EGFR PharmDx kit (Dako) or other standard anti-EGFR antibodies and the response to the EGFR inhibitors.Method:In this study, we investigated the potential of our anti-EGFR monoclonal antibodies (mAbs; ICR9, ICR10, ICR16) for immunohistochemical diagnosis of wild-type EGFR and/or the type-III deletion mutant form of EGFR (EGFRvIII) in formalin-fixed, paraffin-embedded human tumour specimens.Results:We found that the anti-EGFR mAb in the EGFR PharmDx kit stained both wild-type and EGFRvIII-expressing cells in formalin-fixed, paraffin-embedded sections. This pattern of EGFR immunostaining was also found with our anti-EGFR mAb ICR16. In contrast, mAbs ICR10 and ICR9 were specific for the wild-type EGFR.Conclusion:We conclude that mAbs ICR9 and ICR10 are ideal tools for investigating the expression patterns of wild-type EGFR protein in tumour specimens using immunohistochemistry, and to determine their prognostic significance, as well as predictive value for response to therapy with EGFR antibodies.British Journal of Cancer advance online publication, 7 February 2012; doi:10.1038/bjc.2012.27 www.bjcancer.com.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27(12): 2091 - 2096
    • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10): 1626 - 1634
    • Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4): 31 - 39
    • Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52(7): 893 - 901
    • Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28(7): 1254 - 1261
    • Bhargava R, Chen B, Klimstra DS, Saltz LB, Hedvat C, Tang LH, Gerald W, Teruya-Feldstein J, Paty PB, Qin J, Shia J (2006) Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer 106(8): 1857 - 1862
    • Bralet MP, Paule B, Falissard B, Adam R, Guettier C (2007) Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from clonic carcinomas. Histopathology 50: 210 - 216
    • Buckley AF, Kakar S (2007) Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 15(3): 305 - 309
    • Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19(4): 717 - 723
    • Carpenter G (1987) Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56: 881 - 914
    • Chung KY, Shia J, Kemeny NE (2005) Cetuximab shows activity in colorectal cancer patients with tumours that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803 - 1810
    • Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11): 1160 - 1174
    • Cowley G, Smith JA, Gusterson B, Hendler F, Ozanne B (1984) The amount of EGF receptor is elevated on human squamous cell carcinoma. Cancer Cells 1: 5 - 10
    • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab Monotherapy and Cetuximab plus Irinotecan in IrinotecanRefractory Metastatic Colorectal Cancer. N Engl J Med 351(4): 337 - 345
    • Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H (2005) Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 27: 317 - 325
    • De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, PenaultLlorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of KRAS, BRAF, NRAS, and PIK3CAmutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8): 753 - 762
    • Dean C, Modjtahedi H, Eccles S, Box G, Styles J (1994) Immunotherapy with antibodies to the EGF receptor. Int J Cancer Suppl 8: 103 - 107
    • Derecskei K, Moldvay J, Bogos K, Timari J (2006) Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmdx in paraffin-embedded cancer tissues. Pathol Oncol Res 12(4): 241 - 245
    • Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35): 5705 - 5712
    • Ensinger C, Sterlacci W (2008) Implications of EGFR Pharmdx Kit for cetuximab eligibility. Expert Rev Mol Diagn 2: 141 - 148
    • Gullick W (2001) The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer 8(2): 75 - 82
    • Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, Nitta RT, Wong AJ (2010) Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol 10: 72
    • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell. 144(5): 646 - 674
    • Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, Pruvot FR (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17(7): 855 - 857
    • Hecht JR, Mitchell E, Neubauer MA, Burris Iii HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J (2010) Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 16(7): 2205 - 2213
    • Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11(4): 1462 - 1466
    • Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Penault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E, Tejpar S (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27(30): 5068 - 5074
    • Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris III HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22): 3230 - 3237
    • Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H (2011) Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol 39: 483 - 491
    • Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK (2004) Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72(3): 267 - 273
    • Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH (2005) Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 113(3): 510 - 511
    • Ljuslinder I, Malmer B, Isaksson-Metta¨vainio M, O¨ berg A˚, Henriksson R, Stenling R, Palmqvist R (2009) ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Res 29(5): 1489 - 1494
    • Lui VW, Grandis JR (2002) EGFR-mediated cell cycle regulation. Anticancer Res 22(1A): 1 - 11
    • Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14): 2787 - 2799
    • Meropol NJ (2005) Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. J Clin Oncol 23(9): 1791 - 1793
    • Mitchell P (2004) Erbitux diagnostic latest adjunct to cancer therapy. Nat Biotechnol 22(4): 363 - 364
    • Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands: expression, prognostic value, and target for therapy in cancer. Int J Onco 4: 277 - 296
    • Modjtahedi H, Essapen S (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20: 851 - 855
    • Modjtahedi H, Moscatello DK, Box G, Green M, Shoton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S (2003) Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFR VIII) by anti-EGFR MAB ICR62: a two-pronged attack for tumour therapy. Int J Cancer 105: 273 - 280
    • Modjtahedi H, Styles JM, Dean CJ (1993) The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br J Cancer 67: 247 - 253
    • Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55(23): 5536 - 5539
    • Nicholson RI, Gee JW, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37: 9 - 15
    • Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ, Habib FK (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82(1): 186 - 194
    • Oliveras-Ferraros C, Vall-Llovera AM, Salip DC, Vazquez-Martin A, Cufi S, Queralt B, Martin-Castillo B, Brunet J, de Llorens R, Menendez JA (2010) Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Invest New Drugs; DOI:10.1007/s10637-010-9612-2
    • Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Bakhtiari A, Paknejad M, Kashanian S (2004) Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus. Tumour Biol 25(4): 179 - 187
    • Penault-Llorca F, Cayre A, Arnould L, Bibeau F, Bralet MP, Rochaix P, Savary J, Sabourin JC (2006) Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol Rep 16(6): 1173 - 1179
    • Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFRtargeted agents: is there a silver lining? J Clin Oncol 23(22): 5235 - 5246
    • Salomon DS, Bradt R, Ciardiello F, Normano N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183 - 232
    • Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monocolonal antibodies. J Clin Oncol 22(23): 4772 - 4778
    • Schrag D (2004) The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 351(4): 317 - 319
    • Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101(19): 1308 - 1324
    • Singh AB, Harris RC (2005) Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17(10): 1183 - 1193
    • Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87(21): 8602 - 8606
    • Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME (2000) Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 60(11): 3081 - 3087
    • Tos APD, Ellis I (2005) Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods? Eur J Cancer (Oxford, England: 1990) 41(10): 1383 - 1392
    • Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR, Bigner DD (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55(14): 3140 - 3148
    • Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89(7): 2965 - 2969
    • Wong S (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27: 684 - 694
    • Wu M, Rivkin A, Pham T (2008) Panitumumab: Human monoclonal antibody against epidermal growth factor receptor for the treatment of metastatic colorectal cancer. Clin Ther 30: 14 - 29
    • Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Supplement 4): 3 - 8
    • Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2): 127 - 137
    • Yarom N, Marginean C, Moyana T, Gorn-Hondermann I, Birnboim HC, Marginean H, Auer RC, Vickers M, Asmis TR, Maroun J, Jonker D (2010) EGFR expression variance in paired colorectal cancer primary and metastatic tumors. Cancer Biol Ther 10(5): 416 - 421
    • Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117(8): 2051 - 2058
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article